Nordea believes in Novo’s obesity drug
Nordea believes that Novo Nordisk is heading into an easier second half of the year in which the major event will be an FDA decision on the Danish group’s obesity contender – a decision that should go Novo’s way, the bank says.
BY STEFAN SINGH KAILAY
The first half of the year was difficult for Novo Nordisk, but the second half should be much more positive for the Danish diabetes giant, says analysts from Nordea, who also see a high likelihood that the company’s candidate to treat obesity will win approval from the US FDA.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo: It feels like a big deal
For abonnenter
Rebien: The strongest pipeline ever
For abonnenter
Analyst: Obesity competition is good for Novo
For abonnenter
